Laboratory Corporation of America Holdings which can be found using ticker (LH) now have 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $270.00 and $220.00 calculating the mean target price we have $246.07. Given that the stocks previous close was at $218.44 this indicates there is a potential upside of 12.6%. Also worth taking note is the 50 day moving average now sits at $223.61 and the 200 day moving average is $209.60. The company has a market capitalization of 18.12B. The stock price is currently at: $215.47 USD
The potential market cap would be $20,413,116,909 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 49.76, revenue per share of $139.63 and a 3.81% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
